Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed.
Ensembles ofbioRxiv : the preprint server for biology · 2026
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Michael J Malone *Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Chao Huang *Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Yong ZhangState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Yi QiDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Lea WilliamsDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Laura F SuDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jizhong LouState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.ORCID http://orcid.org/0000-0003-4031-6125
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
Viral Assays CoreU19AI128949 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Donna L. Farber, Peter Alan Sims · 2017 to 2026
$26.4M
A streamlined, high-throughput platform for validation of cancer antigen presentation and isolation of cancer antigen reactive T cellsR33CA256086 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BROCK, AMY, JIANG, NING JENNY · 2021 to 2023
$1.1M
NCI NIH HHS P30 CA016520NCI NIH HHS R33 CA256086NIAID NIH HHS P30 AI045008NIAID NIH HHS U19 AI128949U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA016520U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R33CA256086U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P30AI045008U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI66358U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI128949
6 · The paper itself
Abstract
A major concern of COVID-19 is immune escape. While T cells are implicated in protection against severe disease, direct evaluation of their capacity to specifically target SARS-CoV-2 variants remains limited. We aim to narrow this gap by profiling the ability of CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8 · full record | OpenQuestion